Facebook-f Tiktok Instagram Youtube Whatsapp Linkedin
Facebook-f Tiktok Instagram Youtube Whatsapp Linkedin

Doctor Profile

Back

Dr. Liwei Wang

Gastrointestinal Oncology

Professor · Chief Physician · Doctoral Supervisor · MD

Dr. Wang is chairman of the MDT Expert Committee at Renji Hospital, director of the Pancreatic Cancer Diagnosis and Treatment Center at Shanghai Jiao Tong University, director of the Clinical Oncology Drug Trial Base, leader of the Pancreatic Oncology Group under the Oncology Branch of the Chinese Medical Association, a council member of the Chinese Society of Clinical Oncology (CSCO), and the first-term chairman of the Pancreatic Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO).

Clinical Oncology

Pancreatic Cancer Expert

MDT

40+ yrs

Experience

1000+/y

Outpatients

100+

SCI Papers

Expertise

Dr. Wang specializes in the personalized and precision treatment of complex tumors. His research focuses on translational medicine for gastrointestinal cancers—particularly pancreatic cancer—multidisciplinary cancer management, and genomics-guided individualized targeted and immunotherapy.

Professional Background

Since joining the medical field in 1982, Dr. Wang has been continuously working on the frontlines of cancer diagnosis and treatment, with an annual outpatient volume exceeding 1,000.

From 2001 to 2004, Dr. Wang conducted research as a visiting scholar at the University of California, Los Angeles (UCLA) and MD Anderson Cancer Center.

He led the development of China’s first Expert Consensus on the Comprehensive Diagnosis and Treatment of Pancreatic Cancer and the first CSCO Guidelines for the Diagnosis and Treatment of Pancreatic Cancer issued by the Chinese Society of Clinical Oncology.

He has presided over six projects funded by the National Natural Science Foundation, including a major research program, two National Major New Drug Development Projects, and more than ten other grant-funded studies.

He also initiated the establishment of China’s first “Internet-Based Multidisciplinary Consultation Platform for Pancreatic Tumors” and the national registry platform for advanced pancreatic cancer.

Awards & Honors

  • First Prize of Huaxia Medical Science and Technology Award

  • First Prize of Shanghai Medical Science and Technology Progress Award

  • Recognized as Shanghai Medical Craftsman

  • Selected for the Shanghai Pujiang Talent Program

  • Recognized as Shanghai Outstanding Academic Leader

  • Recognized as Leading Talent of Shanghai

Recent Key Publications:

  1. Hu H, Li H, Jiao F, Han T, Zhuo M, Cui J, Li Y, Wang L. Association of a novel point mutation in MSH2 gene with familial multiple primary cancers.J Hematol Oncol.2017 Oct 3;10(1):158. doi: 10.1186/s13045-017-0523-y.

  2. Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.J Clin Oncol 2016;34:1448-1454.

  3. Liu L, Xiang J, Chen R, Fu D, Hong D, Hao J, Li Y, Li J, Li S, Mou Y, Mai G, Ni Q, Peng L, Qin R, Qian H, Shao C, Sun B, Sun Y, Tao M, Tian B, Wang H, Wang J, Wang L, Wang W, Wang W, Zhang J, Zhao G, Zhou J, Yu X. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC). Int J Oncol 2016;48:900-907.

  4. Han T, Jiao F, Hu H, Yuan C, Wang L, Jin ZL, Song WF, Wang LW. EZH2 promotes cell migration and invasion but not alters cell proliferation by suppressing E-cadherin, partly through association with MALAT-1 in pancreatic cancer. Oncotarget 2016.

  5. Jiao F, Hu H, Han T, Zhuo M, Yuan C, Yang H, Wang L, Wang L. Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer. Oncotarget 2016.

  6. Cui J, Quan M, Jiang W, Hu H, Jiao F, Li N, Jin Z, Wang L, Wang Y, Wang L. Suppressed expression of LDHB promotes pancreatic cancer progression via inducing glycolytic phenotype.Med Oncol,32(5):589, 2015.

  7. Jiao F, Hu H, Han T, Yuan C, Wang L, Jin Z, Guo Z, Wang L. Long Noncoding RNA MALAT-1 Enhances Stem Cell-Like Phenotypes in Pancreatic Cancer Cells.Int J Mol Sci,16(4):6677-6693, 2015.

  8. Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J, Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol 2015;16:619-629.

  9. Hang J, Cai B, Xue P, Wang L, Hu H, Zhou Y, Ren S, Wu J, Zhu M, Chen D, Yang H, Wang L. The Joint Effects of Lifestyle Factors and Comorbidities on the Risk of Colorectal Cancer: A Large Chinese Retrospective Case-Control Study.PLoS One 2015;10:e143696.

  10. Xue P, Zhu L, Wan Z, Huang W, Li N, Chen D, Hu J, Yang H, Wang L. A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy.J Cancer Res Clin Oncol, 2015.

  11. Jiang W, Jin Z, Zhou F, Cui J, Wang L, Wang L. High co-expression of Sp1 and HER-2 is correlated with poor prognosis of gastric cancer patients.Surg Oncol,24(3):220-225, 2015.

  12. Song W, Li Q, Wang L, Huang W, Wang L. FoxO1-negative cells are cancer stem-like cells in pancreatic ductal adenocarcinoma.Sci Rep,5:10081, 2015.

  13. Song W, Li Q, Wang L, Wang L. Modulation of FoxO1 expression by miR-21 to promote growth of pancreatic ductal adenocarcinoma.Cell Physiol Biochem,35(1):184-190, 2015.

  14. Jiao F, Hu H, Yuan C, Wang L, Jiang W, Jin Z, Guo Z, Wang L. Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer.Oncol Rep,32(6):2485-2492, 2014.

  15. Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, Cheng Y, Wang Z, Zheng L, Tao M, Zhu X, Ji D, Liu X, Yu H. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.J Clin Oncol 2013;31:3219-3225.

  16. Cai X, Cao W, Ding H, Liu T, Zhou X, Wang M, Zhong M, Zhao Z, Xu Q, Wang L. Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.J Cancer Res Clin Oncol,139(9):1579-1589, 2013.

  17. Kong X, Li L, Li Z, Le X, Huang C, Jia Z, Cui J, Huang S, Wang L, Xie K. Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer.Cancer Res,73(13):3987-3996, 2013.

  18. Huang C, Qiu Z, Wang L, Peng Z, Jia Z, Logsdon C D, Le X, Wei D, Huang S, Xie K. A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis.Cancer Res,72(3):655-665, 2012.

  19. Jiang W, Cui J, Xie D, Wang L. Sp/KLF family and tumor angiogenesis in pancreatic cancer. Curr Pharm Des,18(17):2420-2431, 2012. (IF:4.414)

  20. Gao Y, Jia Z, Kong X, Li Q, Chang D Z, Wei D, Le X, Suyun H, Huang S, Wang L, Xie K. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis.Cancer Res,71(15):5182-5193, 2011.

  21. Jia Z, Gao Y, Wang L, Li Q, Zhang J, Le X, Wei D, Yao JC, Chang DZ, Huang S, Xie K.. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity.Cancer Res. 2010;70(3):1111-1119

  22. Wei D,Wang L, Kanai M, Jia Z, Le X, Li Q, Wang H, Xie K KLF4alpha Upregulation Promotes Cell Cycle Progression and Reduces Survival Time of Patients with Pancreati Cancer.Gastroenterology 2010;139(6):2135-45

Book Appointment

Contact Us

We would love to speak with you.
Feel free to reach out using the below details.

Find us Here

  • +1 8324667523
  • services@chinahealthtrip.com

Fill out the form below!

Doctor Profile

Dr. Liwei Wang

Gastrointestinal Oncology

Professor · Chief Physician · Doctoral Supervisor · MD

Clinical Oncology

Pancreatic Cancer Expert

MDT

Experience

0 +yrs
0 +

Outpatients

0 +

SCI Papers

Second Opinion ＄399

Contact Me

Expertise

Dr. Wang specializes in the personalized and precision treatment of complex tumors. His research focuses on translational medicine for gastrointestinal cancers—particularly pancreatic cancer—multidisciplinary cancer management, and genomics-guided individualized targeted and immunotherapy.

Professional Background

Since joining the medical field in 1982, Dr. Wang has been continuously working on the frontlines of cancer diagnosis and treatment, with an annual outpatient volume exceeding 1,000.

From 2001 to 2004, Dr. Wang conducted research as a visiting scholar at the University of California, Los Angeles (UCLA) and MD Anderson Cancer Center.

He led the development of China’s first Expert Consensus on the Comprehensive Diagnosis and Treatment of Pancreatic Cancer and the first CSCO Guidelines for the Diagnosis and Treatment of Pancreatic Cancer issued by the Chinese Society of Clinical Oncology.

He has presided over six projects funded by the National Natural Science Foundation, including a major research program, two National Major New Drug Development Projects, and more than ten other grant-funded studies.

He also initiated the establishment of China’s first “Internet-Based Multidisciplinary Consultation Platform for Pancreatic Tumors” and the national registry platform for advanced pancreatic cancer.

Awards & Honors

First Prize of Huaxia Medical Science and Technology Award

First Prize of Shanghai Medical Science and Technology Progress Award

Recognized as Shanghai Medical Craftsman

Selected for the Shanghai Pujiang Talent Program

Recognized as Shanghai Outstanding Academic Leader

Recognized as Leading Talent of Shanghai

Professional Background

  1. Hu H, Li H, Jiao F, Han T, Zhuo M, Cui J, Li Y, Wang L. Association of a novel point mutation in MSH2 gene with familial multiple primary cancers.J Hematol Oncol.2017 Oct 3;10(1):158. doi: 10.1186/s13045-017-0523-y.
  2. Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.J Clin Oncol 2016;34:1448-1454.
  3. Liu L, Xiang J, Chen R, Fu D, Hong D, Hao J, Li Y, Li J, Li S, Mou Y, Mai G, Ni Q, Peng L, Qin R, Qian H, Shao C, Sun B, Sun Y, Tao M, Tian B, Wang H, Wang J, Wang L, Wang W, Wang W, Zhang J, Zhao G, Zhou J, Yu X. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC). Int J Oncol 2016;48:900-907.
  4. Han T, Jiao F, Hu H, Yuan C, Wang L, Jin ZL, Song WF, Wang LW. EZH2 promotes cell migration and invasion but not alters cell proliferation by suppressing E-cadherin, partly through association with MALAT-1 in pancreatic cancer. Oncotarget 2016.
  5. Jiao F, Hu H, Han T, Zhuo M, Yuan C, Yang H, Wang L, Wang L. Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer. Oncotarget 2016.
  6. Cui J, Quan M, Jiang W, Hu H, Jiao F, Li N, Jin Z, Wang L, Wang Y, Wang L. Suppressed expression of LDHB promotes pancreatic cancer progression via inducing glycolytic phenotype.Med Oncol,32(5):589, 2015.
  7. Jiao F, Hu H, Han T, Yuan C, Wang L, Jin Z, Guo Z, Wang L. Long Noncoding RNA MALAT-1 Enhances Stem Cell-Like Phenotypes in Pancreatic Cancer Cells.Int J Mol Sci,16(4):6677-6693, 2015.
  8. Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J, Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol 2015;16:619-629.
  9. Hang J, Cai B, Xue P, Wang L, Hu H, Zhou Y, Ren S, Wu J, Zhu M, Chen D, Yang H, Wang L. The Joint Effects of Lifestyle Factors and Comorbidities on the Risk of Colorectal Cancer: A Large Chinese Retrospective Case-Control Study.PLoS One 2015;10:e143696.
  10. Xue P, Zhu L, Wan Z, Huang W, Li N, Chen D, Hu J, Yang H, Wang L. A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy.J Cancer Res Clin Oncol, 2015.
  11. Jiang W, Jin Z, Zhou F, Cui J, Wang L, Wang L. High co-expression of Sp1 and HER-2 is correlated with poor prognosis of gastric cancer patients.Surg Oncol,24(3):220-225, 2015.
  12. Song W, Li Q, Wang L, Huang W, Wang L. FoxO1-negative cells are cancer stem-like cells in pancreatic ductal adenocarcinoma.Sci Rep,5:10081, 2015.
  13. Song W, Li Q, Wang L, Wang L. Modulation of FoxO1 expression by miR-21 to promote growth of pancreatic ductal adenocarcinoma.Cell Physiol Biochem,35(1):184-190, 2015.
  14. Jiao F, Hu H, Yuan C, Wang L, Jiang W, Jin Z, Guo Z, Wang L. Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer.Oncol Rep,32(6):2485-2492, 2014.
  15. Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, Cheng Y, Wang Z, Zheng L, Tao M, Zhu X, Ji D, Liu X, Yu H. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.J Clin Oncol 2013;31:3219-3225.
  16. Cai X, Cao W, Ding H, Liu T, Zhou X, Wang M, Zhong M, Zhao Z, Xu Q, Wang L. Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.J Cancer Res Clin Oncol,139(9):1579-1589, 2013.
  17. Kong X, Li L, Li Z, Le X, Huang C, Jia Z, Cui J, Huang S, Wang L, Xie K. Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer.Cancer Res,73(13):3987-3996, 2013.
  18. Huang C, Qiu Z, Wang L, Peng Z, Jia Z, Logsdon C D, Le X, Wei D, Huang S, Xie K. A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis.Cancer Res,72(3):655-665, 2012.
  19. Jiang W, Cui J, Xie D, Wang L. Sp/KLF family and tumor angiogenesis in pancreatic cancer. Curr Pharm Des,18(17):2420-2431, 2012. (IF:4.414)
  20. Gao Y, Jia Z, Kong X, Li Q, Chang D Z, Wei D, Le X, Suyun H, Huang S, Wang L, Xie K. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis.Cancer Res,71(15):5182-5193, 2011.
  21. Jia Z, Gao Y, Wang L, Li Q, Zhang J, Le X, Wei D, Yao JC, Chang DZ, Huang S, Xie K.. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity.Cancer Res. 2010;70(3):1111-1119
  22. Wei D,Wang L, Kanai M, Jia Z, Le X, Li Q, Wang H, Xie K KLF4alpha Upregulation Promotes Cell Cycle Progression and Reduces Survival Time of Patients with Pancreati Cancer.Gastroenterology 2010;139(6):2135-45

Contact Us

We would love to speak with you.
Feel free to reach out using the below details.

Find us Here

  • +1 8324667523
  • services@chinahealthtrip.com

Fill out the form below!

WhatsApp

Book Your Appointment